(5-bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone

Product Name‌: (5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone (Dapagliflozin Intermediate 2)
‌CAS No.‌: 461432-22-4

🔬 ‌Product Overview‌
A high-purity pharmaceutical intermediate for synthesizing ‌Dapagliflozin‌ (CAS 461432-26-8), a leading ‌SGLT2 inhibitor‌ used to treat type 2 diabetes by reducing glucose reabsorption in kidneys. With ‌≥95% purity‌ (HPLC-certified), it ensures reliable quality in API manufacturing and R&D for diabetes therapeutics. Available in bulk quantities (1kg–25kg) with industrial-grade packaging.

📊 ‌Key Advantages‌
✅ ‌High Purity‌: ≥95% (HPLC/GC-certified), ensuring low impurity levels for API synthesis.
📦 ‌Bulk Availability‌: Customizable packaging (25kg/drum) for industrial and lab-scale use.
💊 ‌Strategic Role‌: Critical intermediate for Dapagliflozin, a $3.5B+ market drug with growing demand.

💊 ‌Applications‌

1. ‌Diabetes Drug Production‌: Key building block for Dapagliflozin API synthesis.

2. ‌Pharmaceutical R&D‌: Supports development of novel SGLT2 inhibitors.

3. ‌Chemical Export‌: Widely used in global pharmaceutical and reagent markets.

📜 ‌Quality Certification‌

• ‌Testing Standards‌: HPLC, GC, and NMR analysis.

• ‌Compliance‌: Meets ISO 9001 and enterprise export specifications.

🌍 ‌Market Trends‌
The global SGLT2 inhibitor market is projected to grow at ‌9.2% CAGR (2025–2030)‌ due to rising diabetes prevalence and patent expirations (2026–2028). Asia-Pacific dominates generic API production, with suppliers offering ‌GMP-ready intermediates‌ gaining traction in cost-sensitive markets.